Psychopharmacologic treatment of children and adolescents with anxiety disorders.
Journal Article (Journal Article;Review)
Over the last decade, psychopharmacologic treatments for pediatric anxiety disorders have been developed and increasingly subjected to randomized, controlled trials. The authors summarize the data concerning the use of tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), atypical anxiolytics, and benzodiazepines. The extant data suggest that SSRIs--both as monotherapy and when combined with psychotherapy--are effective in the treatment of pediatric anxiety disorders. In addition, some TCAs and SNRIs are effective. However, randomized controlled trials do not suggest efficacy for benzodiazepines or the atypical anxiolytic, buspirone, for children and adolescents with anxiety disorders.
Full Text
Duke Authors
Cited Authors
- Strawn, JR; Sakolsky, DJ; Rynn, MA
Published Date
- July 2012
Published In
Volume / Issue
- 21 / 3
Start / End Page
- 527 - 539
PubMed ID
- 22800992
Pubmed Central ID
- 22800992
Electronic International Standard Serial Number (EISSN)
- 1558-0490
Digital Object Identifier (DOI)
- 10.1016/j.chc.2012.05.003
Language
- eng
Conference Location
- United States